Guardant Health, Inc. (NASDAQ: GH - Get Free Report) Director Alex Azar II sold 826 shares of Guarda

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Trans

Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price tar

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co I

Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the fu

Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

You found a great company, then watched it double before you got round to buying.

Bamco Inc. NY bought a new stake in Guardant Health, Inc. (NASDAQ: GH) during the undefined quarter,

Callan Family Office LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the s

On August 24, 2026, Guardant Health Inc (GH) shares fell 4.4% to a current price of $163.18, reflect

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will ap

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

A Delaware federal judge finalized a ruling ordering Guardant Health (NASDAQ:GH) to pay over $245.2

Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million a

Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease,

Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision

Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FD

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight an

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overw

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price

RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raise

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pric

U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other g

Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Kar

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overw

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises th

Evercore ISI Group analyst Vijay Kumar maintains Guardant Health (NASDAQ:GH) with a Outperform an

B of A Securities analyst Michael Ryskin maintains Guardant Health (NASDAQ:GH) with a Buy and rai

Bernstein analyst Eve Burstein maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ:GH) with a Outperform and annou